A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
Clinical trial NCT05668403 · RECRUITING
Trial details
- NCT number
- NCT05668403
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-02
- Primary completion
- 2026-12-30
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.